




































serum	 of	 patients	 included	 into	 the	 study	 showed	 that	 the	 median	 of	 the	
distribution	of	enzyme	was	14.3	 (5.7;	57.8)	ng/ml	 (р<0.05)	 compared	 to	3.8	 (3.2;	
7.5)	 in	 patients	 of	 the	 control	 group.On	 the	 basis	 of	 the	 comparison	 of	 serum	
levels	 of	 NSE	 with	 the	 value	 of	 total	 NIHSS,	 MMSE	 and	 МоСА	 score	 more	
significant	 increase	 in	 this	parameter	was	detected	 in	patients	 with	 profound	
neurologic	 deficit	 and	 MCI.	 The	 analysis	 of	 serum	 NSE	 is	 an	 informative	
diagnostic	criterion	 for	 the	evaluation	of	neuronal	damage	 in	 the	brain	 leading	
























neuron-specific	 enolase	 (NSE)	 in	 particular,	 perform	 several	 functions	 simultaneously:	 they	 are	





neuroendocrine	 tumors,	 oat	 cell	 cancer,	 neuroblastoma,	 traumatic	 brain	 injury,	 epilepsy.	 The	
determination	of	NSE	 is	helpful	after	surgeries	performed	on	patients	 	with	cardiac	pathology	as	
well	as	after	surgical	interventions	using	cardiopulmonary	bypass	[3,	6,	14].	The	promising	direction	
in	 modern	 angioneurology	 is	 the	 use	 of	 NSE	 as	 a	 tumor	 marker	 in	 patients	 with	 acute	
cerebrovascular	disease	 [3,	4,	6,	7].	 In	cerebral	 infarction,	hypoperfusion	of	brain	 tissues	 leads	 to	
neuronal	damage	as	a	result	of	which	NSE	and	other	substances	which	are	defined	as	markers	of	
neuronal	damage	release	[7].	Cell	markers	may	also	release	in	subarachnoidal	hemorrhage	due	to	
ruptured	 aneurysm	 [7,	 14].	 NSE	 is	 an	 important	 marker	 in	 evaluating	 acute	 complications	 as	 it	
correlates	with	the	degree	of	neuronal	damage	and,	therefore,	is	the	prognosis	of	the	diseases.	NSE	
increases	and	 reaches	 its	peak	values	on	 the	 first	day	of	 stroke.	The	primary	 increase	 in	 serum	
levels	of	NSE	is	followed	by	the	secondary	one	which	is	usually	less	significant	being	a	result	of	the	
secondary	damage	 to	brain	 tissues	due	 to	cerebral	edema	and	 increased	 intracranial	pressure	 [7,	








	 There	 were	 examined	 128	 patients	 with	 past	 IS	 (on	 the	 4th	 -5th	 months	 after	 acute	
cerebrovascular	disease)	at	 the	age	of	40-76	years	 (the	average	age	was	58.5	 ±	10.3)	The	diagnosis	
was	made	on	the	basis	of	anamnesis	and	complaints,	neurological	examination,	CT	or	brain	MRI.	
When	 performing	 CT	 or	 MRI	 signs	 of	 ischemic	 lesions	 of	 different	 localization	 and	 size	 were	
observed	 in	 all	 patients.	 The	 etiological	 factor	 for	 stroke	 was	 the	 coexistence	 of	 arterial	
hypertension	 and	 atherosclerotic	 lesion	 of	 the	 extracranial	 portion	 of	 the	 carotid	 arteries	 or	
diabetes	mellitus.		







was	 located	 in	the	 left	hemisphere	 in	77	 (60.1%)	patients	and	 in	51	 (39.8%)	patients	 it	was	 located	
in	 the	 right	hemisphere.	The	 control	group	 included	20	practically	healthy	persons	without	any	
signs	 of	 cerebrovascular	 pathology.	 The	 study	 was	 carried	 out	 at	 the	 department	 of	 vascular	
neurology	of	Ivano-Frankivsk	Regional	Clinical	Hospital	and	the	department	of	neurology	of	Ivano-







	 Neuron-specific	 enolase	 served	 as	 a	 marker	 of	 neuronal	 damage.	 Blood	 sampling	 was	
performed	in	the	morning	after	an	overnight	fast.	The	blood	was	then	centrifuged	at	2000	rpm.	The	
determination	of	NSE	was	performed	in	obtained	serum	samples	on	the	analyzer	by	the	method	of	
a	 solid-phase	 competitive	 enzyme	 immunoassay	using	human	NSE	 ELISA	 kits	produced	 by	DAI	
(USA)	according	to	the	manufacturer’s	instructions.	The	obtained	data	were	statistically	processed	
using	software	package	STATISTICA	6.0.	The	Mann-Whitney	U	test,	a	non-parametric	test	that	 is	





hospitalization	 all	 patients	 were	 divided	 as	 follows:	 45	 (35.1%)	 persons	 with	 mild	 neurological	
disorders	 (6.21±1.71	points);	 55	 (43%)	 persons	 with	 moderate	 neurologic	 impairment	 (10.58±1.04	
points);	28	(21.8%)	persons	with	severe	neurologic	impairment	(15.76±1.95	points).	
	 The	 results	of	 brain	MRI/CT	 revealed	 the	 signs	of	 internal	or	 concomitant	hydrocephaly,	
changes	 in	 the	 cerebral	 hemispheric	 white	 matter	 (focal	 changes,	 leukoaraiosis	 located	
periventricularly	and/or	 in	the	subcortical	regions	of	the	brain,	the	prefrontal	cortex)	generalized	
expansion	of	all	components	of	the	cerebrospinal	fluid	system	with	subsequent	brain	atrophy.	



















	 Enzyme	 immunoassay	 for	 the	 determination	 of	 NSE	 concentration	 in	 blood	 serum	 of	































Parameters	 Group	I	 Group	II	 Control	group	
MMSE	 26.36±0.2*	 24.15±0.19*̂	 29.1±1.1	
МоСА	 24.04±0.17*	 21.6±0.21*̂	 28.05±0.24	






There	were	strong	correlations	between	serum	 level	of	NSE	and	 the	MMSE	score	 (R=-0.78;	





more	 significant	 increase	 in	 this	 parameter	 was	 detected	 in	 patients	 with	 profound	 neurologic	













There	 was	 a	 direct	 correlation	 between	 serum	 NSE	 and	 the	 severity	 of	 neurologic	
impairment	(R=0.71;	p<0.05)	indicating	the	direct	dependence	of	the	degree	of	post-ischemic	brain	
damage	and	neurological	disorders.	NSE	directly	reflects	the	depth	and	intensity	of	structural	and	
functional	 biomembrane	 abnormalities	 in	 the	 central	 nervous	 system,	 the	 severity	 of	
pathomorphological	changes	in	neurons	and	the	degree	of	blood-brain	barrier	permeability	[11,	12].	
	 The	analysis	of	 the	concentration	of	NSE	 in	blood	serum	 revealed	 its	 increase	 in	patients	
with	co-existent	somatic	diseases,	type	II	diabetes	mellitus	(type	II	DM)	and	ischemic	heart	disease	





















































	 3.	The	deterioration	 in	 cognitive	 function	and	high	 serum	 levels	of	NSE	are	predictors	of	
unfavorable	prognosis.	





	 Considering	 the	 prevalence	 and	 variety	 of	 clinical	 manifestations	 of	 this	 pathology	 the	
promising	direction	 is	 the	 study	of	 the	 influence	of	 changes	 in	 the	 concentration	of	markers	of	
post-ischemic	 damage	 and	 adhesion	 molecules	 on	 dynamics	 of	 neurologic	 state	 and	 cognitive	
impairments	 in	patients	with	past	 ischemic	stroke	undergoing	complex	neuroprotective	 therapy	
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